HCM.L - Hutchison China MediTech Limited

LSE - LSE Delayed Price. Currency in GBp

Hutchison China MediTech Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Central
Hong Kong
852 2121 8200
http://www.chi-med.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees714

Key Executives

NameTitlePayExercisedYear Born
Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBAExec. Chairman167.4kN/A1952
Mr. Christian Hogg B.Sc., M.B.A., BSc, MBACEO & Exec. Director1.33MN/A1966
Mr. Johnny Cheng C.A., BEc, CACFO & Exec. Director682.01kN/A1967
Dr. Wei-Guo Su B.Sc., Ph.D.Chief Scientific Officer, Exec. VP & Exec. Director3.13MN/A1957
Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE)Company Sec. & Non-Exec. Director70kN/A1952
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Corporate Governance

Hutchison China MediTech Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.